Ozanimod Approved for Relapsing Forms of Multiple Sclerosis

Although the drug requires no CYP2C9 genotyping or first-dose observation, an up-titration scheme should be used due to the risk of transient cardiac conduction issues.

Source link

Related posts

Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder


Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study


Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD)


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy